购物车
- 全部删除
- 您的购物车当前为空
IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1).
IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 13,100 | 6-8周 |
产品描述 | IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1). |
靶点活性 | CDK7:≤50 nM (Ki), CDK2:≥1000 nM (Ki) |
体外活性 | IV-361 has less inhibition on CDK2 (K i ≥1000 nM) or PLK1 (K i ≥5000 nM)[1]. IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC 50 ≤100 nM) in periphery blood mononuclear cell (PBMC)[1]. IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI 50 ≤100 nM)[1]. |
体内活性 | IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116[1]. |
分子量 | 457.625 |
分子式 | C23H32FN5O2Si |
CAS No. | 2055741-39-2 |
密度 | 1.24 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容